<DOC>
	<DOC>NCT01654250</DOC>
	<brief_summary>The safety and efficacy of a chewable formulation of extended-release methylphenidate will be studied in children with ADHD</brief_summary>
	<brief_title>NWP09 in Children With Attention Deficit Hyperactivity Disorder (ADHD)</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Children aged 6 to 12 years with ADHD who require pharmacologic treatment for this condition Other serious illnesses or conditions that would put the patient at particular risk for safety events or would interfere with treatment/assessment of ADHD</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>ADHD</keyword>
	<keyword>methylphenidate extended-release</keyword>
</DOC>